<DOC>
	<DOCNO>NCT02411019</DOCNO>
	<brief_summary>This study follow change immune response measure HPV type 16/18 E6 E7 specific T cell response lesion condition subject administer DNA-based therapeutic vaccine .</brief_summary>
	<brief_title>Safety Efficacy GX-188E DNA Therapeutic Vaccine Administered Electroporation After Observation</brief_title>
	<detailed_description>This follow-up study investigate change immunogenicity lesion condition subject cervical intraepithelial neoplasia ( CIN ) 3 enrol participate GX-188E phase II trial ( GX-188E_CIN3_P2 ) . Subjects make visit 7 time three year last visit GX-188E phase 2 trial ( GX-188E_CIN3_P2 ) . The endpoint evaluate change immune response , involve lesion infection status compare final visit phase 2 trial ( GX-188E_CIN3_P2 ) .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Those voluntarily sign informed consent form The subject participate phase II trial ( GX188E_CIN3_P2 ) The subject n't receive GX188E DNA vaccine Phase II trial ( GX188E_CIN3_P2 ) The subject , difficult participate study continuously Any ineligible condition discretion investigator would ineligible participate study</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Phase 2 follow</keyword>
	<keyword>Cervical Intraepithelial Neoplasia</keyword>
	<keyword>Adult</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>